The emergence of antimicrobial resistance (AMR) in Escherichia coli poses a significant public health threat. Overuse and misuse of antibiotics in both human and veterinary medicine contribute to the development of resistant strains. Extended-spectrum beta-lactamase (ESBL)-producing E. coli and carbapenem-resistant E. coli (CRE) are among the concerning resistant variants. These strains limit treatment options, leading to prolonged illnesses and increased mortality rates. The spread of AMR E. coli is facilitated through person-to-person transmission, contaminated food and water, and international travel. Surveillance programs monitor the prevalence of AMR, with a particular focus on healthcare settings where resistant strains often emerge. Public health campaigns stress the importance of responsible antibiotic use, adherence to infection prevention measures, and advocating for the development of new antibiotics. Addressing AMR in E. coli requires a global, collaborative effort involving healthcare professionals, researchers, policymakers, and the public to preserve the effectiveness of existing antibiotics and ensure effective treatment options for bacterial infections.